Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Isoaminile is a synthetic small molecule antitussive (cough suppressant) structurally related to methadone. It acts centrally to suppress the cough reflex by influencing the cough center in the central nervous system. Isoaminile also exhibits anticholinergic activity, functioning as both an antimuscarinic and antinicotinic agent, which contributes to its therapeutic effects by inhibiting acetylcholine at muscarinic receptors and reducing bronchial secretions. It is typically administered as a cyclamate or citrate salt, with common brand names including Peracon, Aprecon, and Nullatuss. The drug has been approved for use in treating cough but has also been withdrawn in some regions[1][2][3][5][6][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on isoaminile.